SanBio Company Limited Logo

SanBio Company Limited

Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.

4592 | T

Overview

Corporate Details

ISIN(s):
JP3336750009
LEI:
Country:
Japan
Address:
中央区明石町8番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SanBio Company Limited is a biotechnology firm dedicated to the research, development, production, and commercialization of regenerative cell medicines. The company focuses on creating novel treatments for severe neurological disorders, aiming to restore functions lost due to injury or disease. Its primary pipeline targets conditions affecting the central nervous system, such as chronic motor deficits resulting from traumatic brain injury and stroke. SanBio's lead product candidate, SB623 (marketed in Japan as AKUUGO®), is an allogeneic cell therapy developed to improve motor function in patients. The company leverages its proprietary technology for large-scale production to address significant unmet medical needs in neurology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 01:00
Share Issue/Capital Change
訂正臨時報告書
Japanese 31.2 KB
2025-09-12 08:31
Regulatory Filings
確認書
Japanese 7.9 KB
2025-09-12 08:31
Interim / Quarterly Report
半期報告書-第13期(2025/02/01-2026/01/31)
Japanese 230.6 KB
2025-06-13 08:45
Regulatory Filings
臨時報告書
Japanese 19.2 KB
2025-04-24 08:31
AGM Information
臨時報告書
Japanese 23.7 KB
2025-04-23 08:31
Registration Form
確認書
Japanese 8.0 KB
2025-04-23 08:31
Governance Information
内部統制報告書-第12期(2024/02/01-2025/01/31)
Japanese 21.6 KB
2025-04-23 08:30
Annual Report
有価証券報告書-第12期(2024/02/01-2025/01/31)
Japanese 1.3 MB
2025-03-17 07:30
Earnings Release
臨時報告書
Japanese 21.2 KB
2025-02-14 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 168.5 KB
2024-12-25 07:30
Regulatory Filings
臨時報告書
Japanese 19.3 KB
2024-12-02 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 112.5 KB
2024-09-17 08:02
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-09-17 08:01
Report Publication Announcement
確認書
Japanese 7.9 KB
2024-09-17 08:01
Interim / Quarterly Report
半期報告書-第12期(2024/02/01-2024/07/31)
Japanese 181.0 KB

Automate Your Workflow. Get a real-time feed of all SanBio Company Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SanBio Company Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SanBio Company Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia
ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America
ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America
ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom
AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden
ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
ALLO

Talk to a Data Expert

Have a question? We'll get back to you promptly.